Global Health Limited (GLH) Fair Value & Analysis
Healthcare · AU · Market cap A$3.8M
Fair value as of: Jul 16, 2026
From 2 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from A$0.0726 to A$0.0813 (+12.0%) since Jun 26, 2026.
A solid business, screening 25% undervalued on our models.
What matters now
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (A$0.0553 to A$0.1203) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range A$0.0510 – A$0.7900 · fair‑value band A$0.0553 – A$0.1203 · the A$0.0650 price screens below the A$0.0813 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Global Health Limited (GLH) currently trades at A$0.0650, while our model-based Fair Value estimate is A$0.0813, implying the stock looks roughly 25.1% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Global Health Limited generated revenue of A$8.5M at a net margin of -9.6%. Revenue declined 4.7% year over year. Fundamentals as of Jul 16, 2026
Our scenario range runs from A$0.0553 (bear case) to A$0.1203 (bull case); at A$0.0650, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 52% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at 25%, GLH screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Notify me when GLH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Global Health Limited provides digital health solutions for the healthcare industry in Australia. The company offers software as a service platform and software applications for electronic medical records, client management systems, patient administration systems, practice management systems, clinical records, secure messaging, patient engagement platforms, …
Full company description
Global Health Limited provides digital health solutions for the healthcare industry in Australia. The company offers software as a service platform and software applications for electronic medical records, client management systems, patient administration systems, practice management systems, clinical records, secure messaging, patient engagement platforms, and consumer health records. It is also involved in the development, sale, and support of the application software for the healthcare sector; and development of system integration software that enables data to be exchanged within an enterprise. The company sells its products under the MasterCare, PrimaryClinic, HotHealth, ReferralNet, and Lifecard brands. Global Health Limited was founded in 1985 and is headquartered in Melbourne, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Global Health Limited reported revenue of A$8.7M in FY2025 versus A$7.0M in FY2021, a compound +5.4%/yr. Reported net income was −A$867K in FY2025.
Watch GLH: get an alert when its fair value changes →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare Global Health Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Global Health Limited (GLH) overvalued or undervalued?
What is the fair value of GLH?
What is the quality score of GLH?
What is the revenue of Global Health Limited (GLH)?
What is the net profit margin of GLH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Global Health Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.